In this study, researchers aimed to determine whether younger BRCA1/2 carriers who undergo oophorectomy can receive menopausal hormone therapy without increasing their risk of breast cancer.

The U.S. Food and Drug Administration has granted regular approval to treatment with Rubraca (rucaparib) for the treatment of ...

TRITON3 trial data support FDA traditional approval of rucaparib for treating adults with BRCA-mutated metastatic castration-resistant prostate cancer.

Angelina Jolie's long-rumored relocation plans are very much alive and gaining momentum, according to close sources.

Menopausal hormone therapy (MHT) does not raise breast cancer risk in women with breast cancer gene mutations, while estrogen only MHT leads to reduced risk.

Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.

Angelina Jolie is reportedly preparing to leave Los Angeles behind as she plans a new life abroad focused on privacy, freedom ...

Cedars Sinai gets 30M to establish a specialized BRCA cancer center focusing on research, diagnosis, and treatment in Los Angeles.

SAN ANTONIO – Using menopausal hormone therapy (MHT) was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results ...

Using menopausal hormone therapy (MHT) was not associated with an increased risk of breast cancer in women with inherited mutations in the BRCA1 or BRCA2 genes, according to the results of a matched ...

Johnson & Johnson’s sNDA for Akeega gets US FDA approval to treat patients with BRCA2-mutated mCSPC: Horsham, Pennsylvania Wednesday, December 17, 2025, 13:00 Hrs [IST] Johnson ...

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...